Invitrocue Appoints Professor Masakazu Toi as Clinical Advisor


January 11, 2019 – Invitrocue Limited (ASX: IVQ), a leader healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Masakazu Toi as Clinical Advisor of Invitrocue.

A renowned oncology expert having held various roles as healthcare provider, scholar, and opinion leader, Professor Toi brings strong clinical oncology knowledge and experience especially in breast cancer, as well as a wide network with cancer institutes and hospitals in Japan. Joining at a time when Invitrocue accelerates the global roll-out of it’s proprietary Onco-PDO® personalised cancer screening test, Professor Toi will advise Invitrocue’s research team on clinical validation and cancer menu expansion of Onco-PDO® in Japan. He will also play an important role in identifying and engaging key partners, including local cancer research centres, hospitals and pharmaceutical companies.

Please click below to read full announcement.

Click to download PDF.